Alternative-C Chemotherapy-free combination of Copanlisib with Obinutuzumab (GA 101) in Patients with Previously Untreated Follicular Lymphoma (FL) and High Tumor Burden (Aktiv)
GABe 2016 FIRST LINE THERAPY OF ADVANCED STAGE FOLLICULAR LYMPHOMA IN PATIENTS NOT ELIGIBLE FOR STANDARD IMMUNOCHEMOTHERAPY (Aktiv)
GAZAI Combined modality approach using Obitunuzumab and involved site low dose irradiation in early stage nodal follicular lymphoma. Radiation dose will be adapted for low-responders. (Aktiv)
LBL 2018 International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma (Aktiv)
Zweitlinie oder später
CC-220-NHL-001 A Phase 1/2, Multicenter, Open-Label Study to Assess Safety, Pharmacokinetics, and preliminary efficacy of CC-220, alone and in combination with an anti-CD20 Monoclonal Antibody (MAB) in subjects with relapsed or refractory Lymphomas (Aktiv)
ME-401-003 - TIDAL Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (Aktiv)